Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026)
Neumora Therapeutics' quarterly Debt Ratio came in at 0.34 in Q1 2026, up 20.58% quarter-over-quarter from 0.29 in Q4 2025.
Neumora Therapeutics has reported Debt Ratio for 2 years, with the latest figure at 0.34 in Q1 2026.
- For the quarter ending Q1 2026, Debt Ratio changed N/A year-over-year to 0.34; the trailing twelve-month figure through Mar 2026 stood at 0.34 (changed N/A YoY), and the FY2025 full-year result was 0.29, changed N/A from the prior year.
- Debt Ratio for Q1 2026 stood at 0.34, up from 0.29 in the prior quarter.
- The five-year high for Debt Ratio was 0.34 in Q1 2026, with the low at 0.09 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | 0.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.34 |
| Dec 31, 2025 | 0.29 |
| Sep 30, 2025 | 0.11 |
| Jun 30, 2025 | 0.09 |